Yiu Nam Lau

Yiu Nam Lau is currently the Chairman & Chief Executive Officer at Athenex, Inc. He is also the Executive Chairman at XenoBiotic Laboratories, Inc., Chairman at XBL-China, Inc., Chairman at SinoPhyto Solutions LLC, Vice Chairman at Taivex Therapeutics, Inc., Executive Director at Project: VISION, Inc., Director at Comprehensive Drug Enterprises Ltd., Director at Avalon BioMedical (Management) Ltd., Director at Aiviva Corp., Director at AiViva BioPharma, Inc., Director at C-Mer D&J Technology Ltd., and Director at C-Mer Rainsoptics Ltd. Additionally, Dr. Lau is a Member of The Royal College of Physicians since 1987 and the Managing Partner at Newport Healthcare Advisors LLC since 2007.
Formerly, Dr. Lau was the Chairman & Chief Executive Officer at Ribapharm, Inc. from 2000 to 2003.
He also served as Chairman at Sun Ten Labs Liquidation Co., Senior Director-Antiviral Therapy Research at Schering-Plough Corp., Director at VioQuest Pharmaceuticals, Inc., Director at Ivory Capital Corp., Director at Celsus Therapeutics Plc from 2007 to 2013, Independent Director at Chelsea Therapeutics International Ltd. from 2004 to 2012, Director at Porton Pharma Solutions Ltd. from 2016 to 2019, Independent Non-Executive Director at C-MER Eye Care Holdings Ltd. from 2017 to 2019, and Senior VP, Head-Worldwide Research & Development at Bausch Health Americas, Inc. Dr. Lau also worked as an MD-Healthcare Investment Banking at ROTH Capital Partners LLC in 2005.
Dr. Lau obtained a doctorate degree from the University of Hong Kong in 1984 and another doctorate degree from the same university in 1992.